Although not statistically significant mice injected with ALL cells overexpressing BCL6 had a lower median percentage (45.6% GFP+) of human tumor cells compared to those injected with vector control cells (54.1% GFP+) 24 hours after the conclusion of Ara-C treatment (Figure 5B). Here, BCL6 is linked to neoplasm.